Posted by Michael Wonder on 20 Aug 2022
Axsome Therapeutics announces FDA approval of Auvelity, the first and only oral NMDA receptor antagonist for the treatment of major depressive disorder in adults
19 August 2022 - Auvelity is the first and only rapid-acting oral treatment approved with labelling of statistically significant improvement in depressive symptoms compared to placebo starting at one week 1.
Axsome Therapeutics today announced that the US FDA has approved Auvelity (dextromethorphan hydrobromide with bupropion hydrochloride) extended release tablets for the treatment of major depressive disorder in adults.
